Rare disease therapeutics + US market access
Bridging breakthrough science to the patients who wait for it
Arbormed develops first-in-class therapies for rare and underserved diseases, and brings complex generic medicines
from Korea to the US market.
Pipeline
A focused pipeline, one mission
Four innovative programs from discovery through clinical preparation.
Scroll to explore development stages →
ProgramDiscoveryPreclinicalINDClinical
ARBM-101Wilson's diseasePhase 1a preparation
ARBM-201ARDSIND-enabling
ARBM-301Pendred syndromeCandidate selection
ARBM-401Multiple myelomaDiscovery
ARBM-101
Wilson's disease
Peptide chelator · IND cleared
View program →
ARBM-201
Acute respiratory distress syndrome
Small molecule · Pendrin activity inhibitor
View program →
ARBM-301
Pendred syndrome
Small molecule · Candidate selection
View program →
ARBM-401
Multiple myeloma
PIKfyve inhibitor · Discovery
View program →
Complex generic
A second engine for growth
Alongside novel drug development, Arbormed identifies high-barrier generic products developed with global partners and advances them toward the United States market — building a potential nearer-term revenue engine alongside the innovative pipeline.
See products1
Identify
Source high-barrier products with US commercial potential
2
Develop
Partner with Korean cGMP manufacturers
3
Register
FDA ANDA filing and approval
4
Commercialize
US distribution through local partners